Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02971683 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
NCT02971683 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 149 participants.
The verdict
NCT02971683, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
Study Summary
Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
Interventions
- DRUG Placebo
- DRUG Abatacept subcutaneous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2022-08-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02971683
The ClinicalTrials.gov registry entry for NCT02971683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02971683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02971683 about?
NCT02971683 is a clinical study titled "Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy". Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
What is the current status of trial NCT02971683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2017-05-04. Estimated completion is 2022-08-02.
What interventions are being tested in trial NCT02971683?
The interventions under investigation include: Placebo (DRUG), Abatacept subcutaneous (DRUG).
Who is sponsoring clinical trial NCT02971683?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.